Busca un médico

Jeanne M. Palmer, M.D.

  1. Hematologist
Solicite una Consulta

Publicaciones

  1. Csizmar CM, Saliba AN, Greipp PT, Alkhateeb H, Begna KH, Foran JM, Gangat N, Hogan WJ, Hook CC, Litzow MR, Mangaonkar AA, Palmer JM, Pardanani A, Shah MV, Tefferi A, Torghabeh MH, Wolanskyj-Spinner AP, Patnaik MM, Kaufmann SH, Al-Kali A. FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): The Mayo Clinic experience. Haematologica. 2024 Jun 20 Epub 2024 June 20
    View PubMed
  2. Baranwal A, Gurney M, Basmaci R, Katamesh B, He R, Viswanatha DS, Greipp P, Foran J, Badar T, Murthy H, Yi CA, Palmer J, Mangaonkar AA, Patnaik MM, Litzow MR, Hogan WJ, Begna K, Gangat N, Tefferi A, Al-Kali A, Shah MV, Alkhateeb HB. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms. Haematologica. 2024 Jun 1; 109 (6):1779-1791 Epub 2024 June 01
    View PubMed
  3. Gerds AT, Harrison CN, Kiladjian JJ, Mesa R, Vannucchi AM, Komrokji RS, Bose P, Kremyanskaya M, Mead A, Gotlib J, Rose S, Sanabria F, Marsousi N, Giuseppi MD, Jiang H, Palmer JM, McCaul K, Ribrag V, Passamonti F. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Adv. 2024 May 31 [Epub ahead of print]
    View PubMed
  4. Hudgens S, Verstovsek S, Floden L, Harrison CN, Palmer J, Gupta V, McLornan D, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins AA, Leahy MF, Deheshi S, Donahue R, Klencke BJ, Mesa RA. Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies. Value Health. 2024 May; 27 (5):607-613 Epub 2024 Feb 02
    View PubMed
  5. Yacoub A, Borate U, Rampal RK, Ali H, Wang ES, Gerds AT, Hobbs G, Kremyanskaya M, Winton E, O'Connell C, Goel S, Oh ST, Schiller G, McCloskey J, Palmer J, Holmes H, Hager S, Assad A, Erickson-Viitanen S, Zhou F, Daver N. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results. Blood Adv. 2024 Mar 26; 8 (6):1515-1528
    View PubMed
  6. Kremyanskaya M, Kuykendall AT, Pemmaraju N, Ritchie EK, Gotlib J, Gerds A, Palmer J, Pettit K, Nath UK, Yacoub A, Molina A, Saks SR, Modi NB, Valone FH, Khanna S, Gupta S, Verstovsek S, Ginzburg YZ, Hoffman R, REVIVE Trial Investigators. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. N Engl J Med. 2024 Feb 22; 390 (8):723-735
    View PubMed
  7. Baranwal A, Basmaci R, He R, Viswanatha D, Greipp P, Murthy HS, Foran J, Palmer J, Hogan WJ, Litzow MR, Hefazi M, Mangaonkar A, Shah MV, Al-Kali A, Alkhateeb HB. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms. Blood Adv. 2024 Feb 13; 8 (3):562-570
    View PubMed
  8. Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024 Feb; 99 (2):193-202 Epub 2023 Dec 10
    View PubMed
  9. Tefferi A, Pardanani A, Al-Kali A, Alkhateeb H, McCullough K, Patnaik M, Hogan WJ, Begna K, Elliott MA, Khera N, Palmer JM, Gangat N, Kelemen K, Orazi A, Chen D, Reichard KK. Mast cell cytomorphology and treatment outcome in mast cell leukemia. Am J Hematol 2024 Jan; 99 (1):E5-E8 Epub 2023 Sept 21
    View PubMed
  10. Pardanani A, Tefferi A, Al-Kali A, Patnaik M, Hogan WJ, Begna K, Elliott MA, Khera N, Palmer JM, Gangat N, Orazi A, Kelemen K, Reichard KK, Chen D. Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome. Am J Hematol 2024 Jan; 99 (1):E1-E4 Epub 2023 Sept 09
    View PubMed
  11. Vachhani P, Mascarenhas J, Bose P, Hobbs G, Yacoub A, Palmer JM, Gerds AT, Masarova L, Kuykendall AT, Rampal RK, Mesa R, Verstovsek S. Interferons in the treatment of myeloproliferative neoplasms. Ther Adv Hematol. 2024; 15:20406207241229588 Epub 2024 Feb 19
    View PubMed
  12. Gangat N, McCullough K, Abdelmagid M, Karrar O, Powell M, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Saliba A, Torghabeh MH, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Badar T, Foran J, Palmer J, Sproat L, Yi CA, Tefferi A. Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia. Haematologica. 2024 Jan 1; 109 (1):187-292 Epub 2024 Jan 01
    View PubMed
  13. Palmer J. Are transplant indications changing for myelofibrosis? Hematology Am Soc Hematol Educ Program. 2023 Dec 8; 2023 (1):676-681
    View PubMed
  14. Gaulin C, Craig F, Fortin Ensign S, Robetorye R, Gibson S, Kelemen K, Khera N, Leis J, Tsang M, Rosenthal A, Munoz J, Palmer J, Hilal T. Allogeneic hematopoietic stem cell transplantation in adults with dendritic/histiocytic neoplasms. Leuk Lymphoma. 2023 Dec; 64 (14):2347-2350 Epub 2023 Sept 07
    View PubMed
  15. Huff D, Fortin Ensign S, Ryan MS, Palmer J, Munoz J. Histiocytic Sarcoma Treated with Pembrolizumab: A Case Report and Literature Review. J Immunother Precis Oncol. 2023 Nov; 6 (4):198-202 Epub 2023 Dec 02
    View PubMed
  16. Mesa RA, Harrison C, Palmer JM, Gupta V, McLornan DP, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins AC, Leahy MF, Kawashima J, Ro S, Donahue R, Gorsh B, Deheshi S, Verstovsek S. Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study. Hemasphere. 2023 Nov; 7 (11):e966 Epub 2023 Oct 24
    View PubMed
  17. Mascarenhas J, Migliaccio AR, Kosiorek H, Bhave R, Palmer J, Kuykendall A, Mesa R, Rampal RK, Gerds AT, Yacoub A, Pettit K, Talpaz M, Komrokji R, Kremyanskaya M, Gonzalez A, Fabris F, Johnson K, Dougherty M, McGovern E, Arango Ossa J, Domenico D, Farnoud N, Weinberg RS, Kong A, Najfeld V, Vannucchi AM, Arciprete F, Zingariello M, Falchi M, Salama ME, Mead-Harvey C, Dueck A, Varricchio L, Hoffman R. A Phase Ib Trial of AVID200, a TGFbeta 1/3 Trap, in Patients with Myelofibrosis. Clin Cancer Res. 2023 Sep 15; 29 (18):3622-3632
    View PubMed
  18. Tamari R, McLornan DP, Ahn KW, Estrada-Merly N, Hernandez-Boluda JC, Giralt S, Palmer J, Gale RP, DeFilipp Z, Marks D, van der Poel M, Verdonck LF, Battiwalla M, Diaz MA, Gupta V, Ali H, Litzow MR, Lazarus HM, Gergis U, Bashey A, Liesveld J, Hashmi S, Pu JJ, Beitinjaneh A, Bredeson C, Rizzieri D, Savani BN, Abid MB, Ganguly S, Agrawal V, Ulrike Bacher V, Wirk B, Jain T, Cutler C, Aljurf M, Kindwall-Keller T, Kharfan-Dabaja MA, Hildebrandt GC, Pawarode A, Solh MM, Yared JA, Grunwald MR, Nathan S, Nishihori T, Seo S, Scott BL, Nakamura R, Oran B, Czerw T, Yakoub-Agha I, Saber W. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis. Blood Adv. 2023 Aug 8; 7 (15):3993-4002
    View PubMed
  19. Tibes R, Kosiorek HE, Dueck AC, Palmer J, Sproat L, Bogenberger J, Hashmi S, Mesa R, Hogan W, Litzow MR, Al-Kali A. Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms. Cancer. 2023 Aug 1; 129 (15):2321-2330 Epub 2023 Apr 11
    View PubMed
  20. Moyo TK, Kishtagari A, Villaume MT, McMahon B, Mohan SR, Stopczynski T, Chen SC, Fan R, Huo Y, Moon H, Tang Y, Bejan CA, Childress M, Anderson I, Rawling K, Simons RM, Moncrief A, Caza R, Dugger L, Collins A, Dudley CV, Ferrell PB, Byrne M, Strickland SA, Ayers GD, Landman BA, Mason EF, Mesa RA, Palmer JM, Michaelis LC, Savona MR. PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis. Clin Cancer Res. 2023 Jul 5; 29 (13):2375-2384
    View PubMed
  21. Acosta-Medina AA, Baranwal A, Johnson IM, Kharfan-Dabaja MA, Murthy H, Palmer JM, Sproat L, Mangaonkar A, Shah MV, Hogan WJ, Litzow MR, Tefferi A, Alkhateeb HB. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2023 Jun; 29 (6):360.e1-360.e8 Epub 2023 Feb 09
    View PubMed
  22. Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, Bezerra ED, Garcia-Robledo JE, Bansal R, Johnston PB, Hathcock M, Larsen JT, Bergsagel PL, Wang Y, Reeder CB, Leis JF, Fonseca R, Palmer JM, Gysbers BJ, Mwangi R, Warsame RM, Kourelis T, Hayman SR, Dingli D, Kapoor P, Kumar SK, Durani U, Villasboas JC, Paludo J, Bennani NN, Nowakowski G, Ansell SM, Castro JE, Kharfan-Dabaja MA, Lin Y, Vergidis P, Murthy HS, Munoz J. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 Jun; 23 (6):456-462 Epub 2023 Mar 07
    View PubMed
  23. Mesa RA, Hudgens S, Floden L, Harrison CN, Palmer J, Gupta V, McLornan DP, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins A, Leahy MF, Deheshi S, Donahue R, Klencke BJ, Verstovsek S. Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies. Cancer Med. 2023 May; 12 (9):10612-10624 Epub 2023 Apr 06
    View PubMed
  24. Al-Kali A, Tibes R, Atherton P, Palmer J, Alkhateeb HB, Patnaik M, Begna K, Gangat N, Hashmi S, He R, Litzow M. A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression. Am J Hematol. 2023 Mar; 98 (3):472-480 Epub 2023 Jan 22
    View PubMed
  25. Venable ER, Gagnon MF, Pitel BA, Palmer JM, Peterson JF, Baughn LB, Hoppman NL, Greipp PT, Ketterling RP, Patnaik MS, Kelemen K, Xu X. A TRIP11:: FLT3 gene fusion in a patient with myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions: a case report and review of the literature. Cold Spring Harb Mol Case Stud. 2023 Feb; 9 (1) Epub 2023 Mar 24
    View PubMed
  26. Granroth G, Rosenthal A, McCallen M, Coughlin C, Benson H, Palmer J, Castro JE, Munoz J. Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Provider's Perspective. Curr Oncol Rep. 2022 Dec; 24 (12):1863-1872 Epub 2022 Nov 07
    View PubMed
  27. Pemmaraju N, Kuykendall A, Kremyanskaya M, Ginzburg Y, Ritchie E, Gotlib J, Gerds A, Palmer J, Valone F, O'Connor P, Modi N, Gupta S, Hoffman R, Verstovsek S. MPN-469 Rusfertide (PTG-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in Patients With Polycythemia Vera. Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 Suppl 2:S338-S339
    View PubMed
  28. Palmer J. EXABS-163-MPN Myelofibrosis with Cytopenia. Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 Suppl 2:S70-S71
    View PubMed
  29. Fasolino J, Oklu R, Palmer J, Hommos MS. Polycythemia secondary to renal cysts. J Nephrol. 2022 Jul; 35 (6):1743-1746 Epub 2022 Jan 11
    View PubMed
  30. Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP, Burgess MR, Hege K, Stock W. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Ann Hematol. 2022 Mar; 101 (3):557-569 Epub 2022 Jan 04
    View PubMed
  31. Wiedmeier-Nutor JE, Iqbal M, Muñoz J, Bezerra ED, Garcia JE, Bansal R, Johnston PB, Hathcock M, Larsen JT, Bergsagel PL, Wang Y, Reeder C, Leis JF, Fonseca R, Palmer J, Warsame R, Kourelis T, Hayman SR, Dingli D, Kapoor P, Villasboas JC, Paludo J, Bennani NN, Ansell S, Castro JE, Kharfan-Dabaja MA, Lin Y, Vergidis P, Murthy H, Rosenthal A. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. Transplant Cell Ther. 2022; 28(3):S195-S196.
  32. Mascarenhas J, Passamonti F, Burbury K, El-Galaly TC, Gerds A, Gupta V, Higgins B, Wonde K, Jamois C, Kovic B, Huw LY, Katakam S, Maffioli M, Mesa R, Palmer J, Bellini M, Ross DM, Vannucchi AM, Yacoub A. The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Adv. 2022 Feb 22; 6 (4):1162-1174
    View PubMed
  33. Eckert R, Huberty J, Kurka J, Laird B, Mesa R, Palmer J. A Randomized Pilot Study of Online Hatha Yoga for Physical and Psychological Symptoms Among Survivors of Allogenic Bone Marrow Transplant. Int J Yoga Therap. 2022 Jan 1; 32 (2022)
    View PubMed
  34. Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, Kharfan-Dabaja MA, Palmer J, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, Pidala J, Khimani F, Grunwald MR, Butler C, Hamadani M. Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. Br J Haematol. 2021 Nov; 195 (3):429-432 Epub 2021 July 12
    View PubMed
  35. Langlais BT, Mazza GL, Kosiorek HE, Palmer J, Mesa R, Dueck AC. Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score. J Hematol. 2021 Oct; 10 (5):207-211 Epub 2021 Oct 31
    View PubMed
  36. Gangat N, Guglielmelli P, Szuber N, Begna KH, Patnaik MM, Litzow MR, Al-Kali A, Foran JM, Palmer JM, Alkhateeb H, Elliott MA, Hanson CA, Pardanani A, Mannelli F, Vannucchi AM, Tefferi A. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. Am J Hematol. 2021 Jul 1; 96 (7):781-789 Epub 2021 May 06
    View PubMed
  37. Mesa R, Palmer J, Eckert R, Huberty J. Quality of Life in Myeloproliferative Neoplasms: Symptoms and Management Implications. Hematol Oncol Clin North Am. 2021 Apr; 35 (2):375-390 Epub 2021 Jan 26
    View PubMed
  38. Joshi M, Cook J, McCullough K, Nanaa A, Gangat N, Foran JM, Murthy HS, Kharfan-Dabaja MA, Sproat L, Palmer J, Pardanani A, Tefferi A, Begna K, Elliot M, Al-Kali A, Patnaik M, Shah MV, Hogan WJ, Litzow MR, Alkhateeb HB. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer J 2021 Mar 4; 11 (3):49 Epub 2021 Mar 04
    View PubMed
  39. Gangat N, Morsia E, Foran JM, Palmer JM, Elliott MA, Tefferi A. Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients. Br J Haematol 2020 Dec; 191 (5):e120-e124 Epub 2020 Sept 18
    View PubMed
  40. Gerds AT, Savona MR, Scott BL, Talpaz M, Egyed M, Harrison CN, Yacoub A, Vannucchi A, Mead AJ, Kiladjian JJ, O'Sullivan J, Garcia-Gutierrez V, Bose P, Rampal RK, Miller CB, Palmer J, Oh ST, Buckley SA, Mould DR, Ito K, Tyavanagimatt S, Smith JA, Roman-Torres K, Devineni S, Craig AR, Mascarenhas JO. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv. 2020 Nov 24; 4 (22):5825-5835
    View PubMed
  41. Mountjoy L, Jain T, Kunze KL, Khera N, Sproat LZ, Jennifer W, McCallen M, Leis JF, Noel P, Slack JL, Palmer J. Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2020 Aug; 61 (8):1996-2002 Epub 2020 Apr 13
    View PubMed
  42. Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, Giralt SA, LeMaistre CF, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Veys PA, Carpenter PA, Hamadani M. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020 Jul; 26 (7):1247-1256 Epub 2020 Mar 09
    View PubMed
  43. Jain T, Kunze KL, Mountjoy L, Partain DK, Kosiorek H, Khera N, Hogan WJ, Roy V, Slack JL, Noel P, Fauble VDS, Leis JF, Sproat L, Tefferi A, Patnaik MM, Mesa RA, Palmer J. Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer J. 2020 Mar 10; 10 (3):36
    View PubMed
  44. Scheckel CJ, Meyer M, Betcher JA, Al-Kali A, Foran J, Palmer J. Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'. Leuk Res. 2020 Mar; 90:106300 Epub 2020 Jan 28
    View PubMed
  45. Palmer J, Mesa R. The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis. Ther Adv Hematol. 2020; 11:2040620720925201 Epub 2020 May 15
    View PubMed
  46. Pidala JA, Hamilton BK, Martin PJ, Onstad L, Storer BE, Palmer J, Alousi A, Cutler C, Jagasia MH, Chen GL, Arora M, Flowers ME, Lee SJ. The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. Biol Blood Marrow Transplant. 2019 Dec; 25 (12):2468-2473 Epub 2019 Aug 05
    View PubMed
  47. Palmer J, Kosiorek HE, Wolschke C, Fauble VDS, Butterfield R 3rd, Geyer H, Scherber RM, Dueck AC, Gathany A, Mesa RA, Kroger N. Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis. Biol Blood Marrow Transplant. 2019 Nov; 25 (11):2267-2273 Epub 2019 July 06
    View PubMed
  48. Martin PJ, Storer BE, Palmer J, Jagasia MH, Chen GL, Broady R, Arora M, Pidala JA, Hamilton BK, Lee SJ. Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2019 Sep; 25 (9):1869-1874 Epub 2019 May 11
    View PubMed
  49. Jain T, Kunze KL, Khetarpal BK, McCallen MR, Betcher JA, Ofori HT, Khera N, Slack JL, Leis JF, Sproat LZ, Noel P, Palmer J. Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter? Leuk Lymphoma. 2019 Aug; 60(8):2034-2041. Epub 2019 Jan 10.
    View PubMed
  50. Jain T, Alahdab F, Firwana B, Sonbol MB, Almader-Douglas D, Palmer J. Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant. 2019 Apr; 25 (4):728-733 Epub 2018 Nov 22
    View PubMed
  51. Palmer J, Scherber R, Girardo M, Geyer H, Kosiorek H, Dueck A, Jain T, Mesa R. Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis. Biol Blood Marrow Transplant. 2019 Feb; 25 (2):398-402 Epub 2018 Oct 04
    View PubMed
  52. Jain T, Sonbol MB, Firwana B, Kolla KR, Almader-Douglas D, Palmer J, Fonseca R. High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant. 2019 Feb; 25 (2):239-247 Epub 2018 Sept 20
    View PubMed
  53. Jain T, Kunze KL, Temkit M, Partain DK, Patnaik MS, Slack JL, Khera N, Hogan WJ, Roy V, Noel P, Leis JF, Sproat LZ, Fauble V, Mesa RA, Palmer J. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2019 Feb; 54 (2):204-211 Epub 2018 May 24
    View PubMed
  54. Jain T, Kosiorek HE, Grys TE, Kung ST, Shah VS, Betcher JA, Slack JL, Leis JF, Khera N, Noel P, Palmer JM, Sproat LZ. Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation. Leuk Lymphoma. 2019 Jan; 60 (1):110-117 Epub 2018 July 06
    View PubMed
  55. El-Jawahri A, Pidala J, Khera N, Wood WA, Arora M, Carpenter PA, Palmer J, Flowers ME, Jagasia M, Chen YB, Lee SJ. Impact of Psychological Distress on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2018 Nov; 24 (11):2285-2292 Epub 2018 July 20
    View PubMed
  56. Holtan SG, DeFor TE, Panoskaltsis-Mortari A, Khera N, Levine JE, Flowers MED, Lee SJ, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Cutler CS, Arai S, Lazaryan A, Newell LF, Jagasia MH, Pusic I, Wood WA, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Bunworasate U, Efebera YA, Ferrara JLM, Pidala J, Howard A, Wu J, Bolanos-Meade J, Ho V, Alousi A, Blazar BR, Weisdorf DJ, MacMillan ML. Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. Blood Adv. 2018 Aug 14; 2 (15):1882-1888
    View PubMed
  57. Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA, Palmer J, Chow E, Meyer E, Marks D, Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, Komanduri KV, Pidala J, Hamadani M, Johnston L, Shah N, Shaughnessy P, Hamilton BK, Majhail N, Kharfan-Dabaja MA, Schriber J, DeFilipp Z, Tarlock KG, Fanning S, Curtin P, Rizzo JD, Carpenter PA. ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. Biol Blood Marrow Transplant. 2018 Jun; 24 (6):1119-1124 Epub 2018 Mar 30
    View PubMed
  58. Tefferi A, Partain DK, Palmer JM, Slack JL, Roy V, Hogan WJ, Litzow ML, Ketterling RP, Patnaik MM. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. Am J Hematol. 2018 May; 93 (5):649-654 Epub 2018 Feb 24
    View PubMed
  59. Hamilton BK, Rybicki L, Arai S, Arora M, Cutler CS, Flowers MED, Jagasia M, Martin PJ, Palmer J, Pidala J, Majhail NS, Lee SJ, Khera N. Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. Biol Blood Marrow Transplant. 2018 Feb; 24 (2):393-399 Epub 2017 Oct 12
    View PubMed
  60. Jain T, Mesa RA, Palmer JM. Allogeneic Stem Cell Transplantation in Myelofibrosis. Biol Blood Marrow Transplant. 2017 Sep; 23 (9):1429-1436 Epub 2017 May 10
    View PubMed
  61. Martin PJ, Storer BE, Inamoto Y, Flowers MED, Carpenter PA, Pidala J, Palmer J, Arora M, Jagasia M, Arai S, Cutler CS, Lee SJ. An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. Blood. 2017 Jul 20; 130 (3):360-367 Epub 2017 May 11
    View PubMed
  62. Palmer J, Mesa R. Transplantation in Myelofibrosis Reaches the Molecular Age. Biol Blood Marrow Transplant 2017 Jul; 23 (7):1043-1044 Epub 2017 May 02
    View PubMed
  63. Ertz-Archambault N, Kosiorek H, Taylor GE, Kelemen K, Dueck A, Castro J, Marino R, Gauthier S, Finn L, Sproat LZ, Palmer J, Mesa RA, Al-Kali A, Foran J, Tibes R. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol. 2017 Jul 1; 3 (7):936-943
    View PubMed
  64. Holtan SG, Khera N, Levine JE, Chai X, Storer B, Liu HD, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Flowers MED, Cutler CS, Lukez A, Arai S, Lazaryan A, Newell LF, Krupski C, Jagasia MH, Pusic I, Wood W, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Watanaboonyongcharoen P, Efebera YA, Ferrara JLM, Panoskaltsis-Mortari A, Weisdorf D, Lee SJ, Pidala J. Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. Blood. 2016 Nov 10; 128 (19):2350-2358 Epub 2016 Sept 13
    View PubMed
  65. Palmer J, McCune JS, Perales MA, Marks D, Bubalo J, Mohty M, Wingard JR, Paci A, Hassan M, Bredeson C, Pidala J, Shah N, Shaughnessy P, Majhail N, Schriber J, Savani BN, Carpenter PA. Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant. 2016 Nov; 22 (11):1915-1925 Epub 2016 July 29
    View PubMed
  66. Cheng GS, Storer B, Chien JW, Jagasia M, Hubbard JJ, Burns L, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S, Crothers K, Pusic I, Lee SJ, Williams KM. Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant. Ann Am Thorac Soc. 2016 Nov; 13 (11):1932-1939
    View PubMed
  67. Palmer J. Early Detection is Key: Is Handheld Spirometry the Answer? Biol Blood Marrow Transplant. 2016 May; 22: (5)780-1.
    View PubMed
  68. Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S, Chien JW, Jacobsohn DA, Pavletic SZ, Martin PJ, Storer BE, Inamoto Y, Chai X, Flowers MED, Lee SJ, Lee SJ. Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Apr; 22 (4):710-716 Epub 2015 Oct 22
    View PubMed
  69. Arora M, Cutler CS, Jagasia MH, Pidala J, Chai X, Martin PJ, Flowers ME, Inamoto Y, Chen GL, Wood WA, Khera N, Palmer J, Duong H, Arai S, Mayer S, Pusic I, Lee SJ. Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Mar; 22 (3):449-55 Epub 2015 Nov 02
    View PubMed
  70. Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N, Palmer J, Chen GL, Jagasia MH, Mayer SA, Wood WA, Green M, Hyun TS, Inamoto Y, Storer BE, Miklos DB, Shulman HM, Martin PJ, Sarantopoulos S, Lee SJ, Flowers ME. A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clin Cancer Res. 2016 Jan 15; 22 (2):319-27 Epub 2015 Sept 16
    View PubMed
  71. Palmer J, Chai X, Pidala J, Inamoto Y, Martin PJ, Storer B, Pusic I, Flowers ME, Arora M, Pavletic SZ, Lee SJ. Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. Blood. 2016 Jan 7; 127 (1):160-6 Epub 2015 Nov 02
    View PubMed
  72. Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Savani BN, Veys PA, Bredeson CN, Giralt SA, LeMaistre CF. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015 Nov; 21 (11):1863-1869 Epub 2015 Aug 07
    View PubMed
  73. Graff TM, Singavi AK, Schmidt W, Eastwood D, Drobyski WR, Horowitz M, Palmer J, Pasquini M, Rizzo DJ, Saber W, Hari P, Fenske TS. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone Marrow Transplant. 2015 Jul; 50 (7):947-53 Epub 2015 Apr 13
    View PubMed
  74. Palmer J, Chai X, Martin PJ, Weisdorf D, Inamoto Y, Pidala J, Jagasia M, Pavletic S, Cutler C, Vogelsang G, Arai S, Flowers ME, Lee SJ. Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. Haematologica. 2015 May; 100 (5):690-5 Epub 2015 Feb 24
    View PubMed
  75. Khera N, Chang YH, Slack J, Fauble V, Leis JF, Noel P, Sproat L, Palmer J, Adams R, Fitch T, Northfelt D, Guy M, Tilburt J, Mikhael J. Impact of race and ethnicity on outcomes and health care utilization after allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2015 Apr; 56 (4):987-92 Epub 2014 Aug 20
    View PubMed
  76. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015 Mar; 21 (3):389-401.e1 Epub 2014 Dec 18
    View PubMed
  77. Inamoto Y, Martin PJ, Storer BE, Palmer J, Weisdorf DJ, Pidala J, Flowers ME, Arora M, Jagasia M, Arai S, Chai X, Pavletic SZ, Vogelsang GB, Lee SJ, Chronic GVHD Consortium. Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica. 2014 Oct; 99 (10):1618-23 Epub 2014 July 04
    View PubMed
  78. El-Jawahri A, Pidala J, Inamoto Y, Chai X, Khera N, Wood WA, Cutler C, Arora M, Carpenter PA, Palmer J, Flowers M, Weisdorf D, Pavletic S, Jaglowski S, Jagasia M, Lee SJ, Chen YB. Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Sep; 20 (9):1341-8 Epub 2014 May 09
    View PubMed
  79. Inamoto Y, Jagasia M, Wood WA, Pidala J, Palmer J, Khera N, Weisdorf D, Carpenter PA, Flowers ME, Jacobsohn D, Martin PJ, Lee SJ, Pavletic SZ, Chronic GVHD Consortium. Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD. Bone Marrow Transplant. 2014 Apr; 49 (4):532-8 Epub 2014 Jan 27
    View PubMed
  80. Palmer J, Williams K, Inamoto Y, Chai X, Martin PJ, Tomas LS, Cutler C, Weisdorf D, Kurland BF, Carpenter PA, Pidala J, Pavletic SZ, Wood W, Jacobsohn D, Arai S, Arora M, Jagasia M, Vogelsang GB, Lee SJ. Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Mar; 20 (3):337-44 Epub 2013 Dec 04
    View PubMed
  81. Pidala J, Wang T, Haagenson M, Spellman SR, Askar M, Battiwalla M, Baxter-Lowe LA, Bitan M, Fernandez-Vina M, Gandhi M, Jakubowski AA, Maiers M, Marino SR, Marsh SG, Oudshoorn M, Palmer J, Prasad VK, Reddy V, Ringden O, Saber W, Santarone S, Schultz KR, Setterholm M, Trachtenberg E, Turner EV, Woolfrey AE, Lee SJ, Anasetti C. Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood. 2013 Nov 21; 122: (22)3651-8.
    View PubMed
  82. Wood WA, Chai X, Weisdorf D, Martin PJ, Cutler C, Inamoto Y, Wolff D, Pavletic SZ, Pidala J, Palmer JM, Arora M, Arai S, Jagasia M, Storer B, Lee SJ, Mitchell S. Comorbidity burden in patients with chronic GVHD. Bone Marrow Transplant. 2013 Nov; 48: (11)1429-36.
    View PubMed
  83. Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, Fenske TS, Horowitz MM, Komorowski R, Palmer J, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR. Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2013 Sep; 19: (9)1368-73.
    View PubMed
  84. Treister N, Chai X, Kurland B, Pavletic S, Weisdorf D, Pidala J, Palmer J, Martin P, Inamoto Y, Arora M, Flowers M, Jacobsohn D, Jagasia M, Arai S, Lee SJ, Cutler C. Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium. Bone Marrow Transplant. 2013 Aug; 48 (8):1123-8 Epub 2013 Jan 28
    View PubMed
  85. Pidala J, Chai X, Martin P, Inamoto Y, Cutler C, Palmer J, Weisdorf D, Pavletic S, Arora M, Jagasia M, Jacobsohn D, Lee SJ. Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium. Biol Blood Marrow Transplant. 2013 Jun; 19: (6)967-72.
    View PubMed
  86. Pidala J, Chai X, Kurland BF, Inamoto Y, Flowers ME, Palmer J, Khera N, Jagasia M, Cutler C, Arora M, Vogelsang G, Lee SJ. Analysis of gastrointestinal and hepatic chronic graft-versus-host [corrected] disease manifestations on major outcomes: a chronic graft-versus-host [corrected] disease consortium study. Biol Blood Marrow Transplant. 2013 May; 19: (5)784-91.
    View PubMed
  87. Arora M, Pidala J, Cutler CS, Chai X, Kurland B, Jacobsohn DA, Pavletic SZ, Palmer J, Vogelsang G, Jagasia M, Schultz K, Lee SJ. Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study. Leukemia. 2013 Apr; 27: (5)1196-201.
    View PubMed
  88. Palmer JM, Lee SJ, Chai X, Storer BE, Flowers ME, Schultz KR, Inamoto Y, Cutler C, Pidala J, Arora M, Jacobsohn DA, Carpenter PA, Pavletic SZ, Martin PJ. Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012 Nov; 18: (11)1649-55.
    View PubMed
  89. Inamoto Y, Martin PJ, Chai X, Jagasia M, Palmer J, Pidala J, Cutler C, Pavletic SZ, Arora M, Jacobsohn D, Carpenter PA, Flowers ME, Khera N, Vogelsang GB, Weisdorf D, Storer BE, Lee SJ, Chronic GVHD Consortium. Clinical benefit of response in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012 Oct; 18: (10)1517-24.
    View PubMed
  90. Jacobsohn DA, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM, Arai S, Arora M, Jagasia M, Cutler C, Weisdorf D, Martin PJ, Pavletic SZ, Vogelsang G, Lee SJ, Flowers ME. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood. 2012 Sep 27; 120: (13)2545-52; quiz 2774.
    View PubMed
  91. Ballen KK, Klein JP, Pedersen TL, Bhatla D, Duerst R, Kurtzberg J, Lazarus HM, LeMaistre CF, McCarthy P, Mehta P, Palmer J, Setterholm M, Wingard JR, Joffe S, Parsons SK, Switzer GE, Lee SJ, Rizzo JD, Majhail NS. Relationship of race ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2012 Jun; 18: (6)903-12.
    View PubMed
  92. Inamoto Y, Chai X, Kurland BF, Cutler C, Flowers ME, Palmer JM, Carpenter PA, Heffernan MJ, Jacobsohn D, Jagasia MH, Pidala J, Khera N, Vogelsang GB, Weisdorf D, Martin PJ, Pavletic SZ, Lee SJ, Chronic GVHD Consortium. Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology. 2012 Mar; 119: (3)487-93.
    View PubMed
  93. Pidala J, Vogelsang G, Martin P, Chai X, Storer B, Pavletic S, Weisdorf DJ, Jagasia M, Cutler C, Palmer J, Jacobsohn D, Arai S, Lee SJ. Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica. 2012 Mar; 97: (3)451-8.
    View PubMed
  94. Drobyski WR, Pasquini M, Kovatovic K, Palmer J, Douglas Rizzo J, Saad A, Saber W, Hari P. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant. 2011 Dec; 17: (12)1862-8.
    View PubMed
  95. Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, Arora M, Weisdorf DJ, Flowers ME, Martin PJ, Palmer J, Jacobsohn D, Pavletic SZ, Vogelsang GB, Lee SJ. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011 Oct 13; 118: (15)4242-9.
    View PubMed
  96. Palmer J, Goggins T, Broadwater G, Chao N, Horwitz M, Beaven A, Sullivan K, Coleman RE, Rizzieri D. Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant. 2011 Jun; 46: (6)847-51.
    View PubMed
  97. Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, Cutler C, Jacobsohn D, Palmer J, Arai S, Jagasia M, Lee SJ. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011 Apr 28; 117: (17)4651-7.
    View PubMed
  98. Palmer JM, Chen BJ, DeOliveira D, Le ND, Chao NJ. Novel mechanism of rapamycin in GVHD: increase in interstitial regulatory T cells. Bone Marrow Transplant. 2010 Feb; 45: (2)379-84.
    View PubMed
PST-20216848